Status:
COMPLETED
A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Lead Sponsor:
Guangzhou Henovcom Bioscience Co. Ltd.
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this First-in-Human study is to evaluate the safety , tolerability，PK and PD after single ascending of HNC664 given to healthy subjects, compared to placebo. Also, food effect will be e...
Eligibility Criteria
Inclusion
- Healthy volunteer, age 18-65 years
- BMI between 18-32 kg/m2,and body weight not less than 50.0kg.
Exclusion
- Any condition that might interfere with the procedures or tests in this study
- Drug or alcohol abuse
- Smoking
Key Trial Info
Start Date :
August 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 13 2021
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04504448
Start Date
August 11 2020
End Date
July 13 2021
Last Update
August 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmaron
Baltimore, Maryland, United States, 21201